Repligen Valuation Multiples

Repligen Overview

About Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

Founded

1981

HQ

Employees

1.8K

Website

repligen.com

Sectors

Contract Research & ManufacturingLaboratory ServicesBioTech

Financials (LTM)

Revenue: $758M

EBITDA: $146M

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Repligen Financials

Repligen reported last 12-month revenue of $758M and EBITDA of $146M.

In the same LTM period, Repligen generated $399M in gross profit, $146M in EBITDA, and $100M in net income.

Repligen P&L

In the most recent fiscal year, Repligen reported revenue of $738M and EBITDA of $181M.

Repligen expects next 12-month revenue of XXX and NTM EBITDA of XXX

Repligen Stock Performance

Repligen has current market cap of $7B, and enterprise value of $7B.

Repligen's stock price is $125.84.

Repligen Valuation Multiples

Repligen trades at 9.3x EV/Revenue multiple, and 48.0x EV/EBITDA.

Repligen Financial Valuation Multiples

As of March 22, 2026, Repligen has market cap of $7B and EV of $7B.

Equity research analysts estimate Repligen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Repligen has a P/E ratio of 70.8x.

Repligen Margins & Growth Rates

Repligen's revenue in the last 12 month grew by 13%.

Repligen's revenue per employee in the last FY averaged $0.4M.

Repligen's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Repligen's rule of X is 51% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Repligen Public Comps

See public comps and valuation multiples for other Contract Research & Manufacturing and Laboratory Services comps.

Repligen M&A Activity

Repligen acquired XXX companies to date.

Last acquisition by Repligen was on XXXXXXXX, XXXXX. Repligen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Repligen Investment Activity

Repligen invested in XXX companies to date.

Repligen made its latest investment on XXXXXXXX, XXXXX. Repligen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).